A practitioner read of HLF at $12.34: a 40-year consumer franchise throwing off ~$668M of trailing adjusted EBITDA, an April 2026 senior-secured refinancing that locks in ~$45M of annual cash interest savings, and a deleveraging trajectory from 3.5x to 1.5x net — trading at multiples typically reserved for distressed businesses, not for a brand of this durability.
The full case study, valuation model, and library crosswalk — all free, all built from public filings.
HLF trades at $12.34 ($1.34B market cap) — roughly 4.3x trailing EV/Adjusted EBITDA and 5.4x earnings — multiples typically reserved for distressed businesses, not for a brand throwing off ~$668M of trailing adjusted EBITDA. The April 29, 2026 senior-secured refinancing locks in ~$45M of annual cash interest savings, deleveraging from 2.3x net at Q1 toward 1.5x net by FY 2027. Cumulative debt repaid 2023–2028E projects at ~$1,315M — a 55% reduction from the 2022 peak.
Owner Earnings (Buffett method) at 8–10x post-refi run-rate: $26–$33. EV/Adjusted EBITDA at 5–7x consumer-staples-MLM-peer comp: $15–$25. DCF mid-case at 8.5% WACC: $28–$32. The lower-bound $14 reflects pure cycle-trough comp pricing; the upper-bound $28 reflects a partial re-rate toward consumer-staples norms. Vs. the $12.34 close, even the conservative lens implies meaningful upside. The LBO lens (5.1x EV/EBITDA at $17 entry, $250–350M annual FCF supporting rapid deleveraging) produces ~35% sponsor IRR over a 5-year hold — a sanity check that the underlying business supports the valuation case.
The multiple discount on HLF reads, in the author's view, as regulatory-tail-driven rather than fundamentals-driven. The market continues to price in the 2016 FTC consent-decree overhang and the MLM-business-model skepticism that intensified during the 2012–2019 Icahn-vs-Ackman battle — even as the business has continued to generate $617–668M of adjusted EBITDA every year for the last five. The April 2026 refinancing + the Bioniq personalization tuck-in + the Asia Pacific +20.8% constant-currency growth all suggest a business in transition that the market has not re-priced. The author's lens; not a price target, not a recommendation.
Independent editorial analysis · Not affiliated with or endorsed by Herbalife Ltd..
This case study is independent editorial and educational analysis of publicly available information about Herbalife Ltd.. The Baratelli Institute is not affiliated with, endorsed by, sponsored by, or otherwise connected to Herbalife Ltd.. Herbalife®, Herbalife Nutrition® and related marks are the property of their respective owners. No claim is made to any such marks by the Baratelli Institute. Analysis draws exclusively on publicly disclosed information (SEC filings, press releases, earnings call transcripts, investor materials, journalist reporting); no non-public information has been received from Herbalife Ltd.. Presented for educational and editorial purposes under principles of fair use and fair comment on a publicly traded company. Nothing in this analysis constitutes investment advice or a recommendation to buy, sell, or hold securities. Consult licensed advisors before investment decisions.
The author, Phil Baratelli, has owned HLF previously and intends to invest. This is an educational case study, not investment advice, not a research report, not a buy/sell rating, not a price target, not an allocation recommendation, not an opinion of fairness for any corporate transaction. Every number traces to a public SEC filing (10-K, 10-Q, 8-K, press releases through May 2026). Readers considering an HLF position should consult their own qualified advisors and conduct their own diligence. The Institute is not a registered investment adviser; this is a Lowe v. SEC publisher-exception publication.
Every analytical move in this case study cross-references a Guide chapter. If you want to learn the methodology in full, the Guides are where it's taught.
“Practitioner case studies — written by an owner, the methodology of the Guides applied to a stock he owns, with the workpapers behind it.”